GLS and acute myeloid leukemia: Telaglenastat (CB-839) is an oral glutaminase inhibitor that was found to inhibit both GLS1, an important enzyme in increasing intracellular glutamine levels, and glutathione, an important antioxidant that neutralizes the high levels of ROS in AML cells.